Birchview Capital’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Birchview Capital’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-48,448	Closed	-$1.69M	–	63
2024 Q1	$1.69M	Hold	48,448	–	–	1.38%	17
2023 Q4	$1.84M	Sell	48,448 -22,000	-31%	-$471K	1.44%	15
2023 Q3	$1.29M	Hold	70,448	–	–	1.1%	19
2023 Q2	$1.83M	Hold	70,448	–	–	1.37%	15
2023 Q1	$1.33M	Hold	70,448	–	–	1.04%	16
2022 Q4	$1.74M	Hold	70,448	–	–	1.23%	14
2022 Q3	$1.26M	Hold	70,448	–	–	0.89%	22
2022 Q2	$800K	Buy	70,448 +20,000	+40%	+$294K	0.58%	26
2022 Q1	$1.12M	Buy	50,448 +10,448	+26%	+$267K	0.81%	21
2021 Q4	$1.75M	Buy	+40,000	New	+$1.6M	1.13%	15

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Birchview Capital's INBX Position: Q2 2024 in Review

Birchview Capital sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 48,448 shares — an estimated $1.69M sold.

Birchview Capital first reported a position in INBX in Q4 2021 and held it in 10 quarters. The position peaked at $1.84M in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

Birchview Capital reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Birchview Capital sold 48,448 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $1.69M.
Birchview Capital first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 10 quarters.
Birchview Capital's Inhibrx, Inc. Common Stock position peaked at $1.84M in Q4 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Birchview Capital's 13F filing for Q2 2024, filed 13 Aug 2024.